Uptake kinetics of the somatostatin receptor ligand [86Y]DOTA-DPhe1-Tyr3-octreotide ([86Y]SMT487) using positron emission tomography in non-human primates and calculation of radiation doses of the 90Y-labelled analogue

European Journal of Nuclear Medicine

Volumn 26, Issue 4, 1999, Pages 358-366

  Rösch, Frank ^b   Herzog, Hans ^c   Stolz, Barbara ^a   Brockmann, Jörg ^c   Köhle, Martin ^c   Mühlensiepen, Heinz ^c   Marbach, Peter ^a   Müller Gärtner, Hans Wilhelm ^c  

^a NOVARTIS PHARMA AG   (Switzerland)

^b JOHANNES GUTENBERG UNIVERSITY   (Germany)

^c NONE

Author keywords

Dosimetry; Octreotide; Positron emission tomography; Yttrium 86; Yttrium 90

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE N,N,N,N,TETRAACETIC ACID OCTREOTIDE[DEXTRO PHENYLALANINE 1 TYROSINE 3]; AMINO ACID; LIGAND; LYSINE; OCTREOTIDE; SOMATOSTATIN DERIVATIVE; SOMATOSTATIN RECEPTOR; UNCLASSIFIED DRUG; YTTRIUM 90;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BABOON; BONE; BONE MARROW; DOSE RESPONSE; DOSIMETRY; KIDNEY TUBULE ABSORPTION; LIVER; LUNG; NONHUMAN; PHASE 1 CLINICAL TRIAL; POSITRON EMISSION TOMOGRAPHY; PRACTICE GUIDELINE; RECEPTOR BINDING; TISSUE DISTRIBUTION; TUMOR; WHOLE BODY SCINTISCANNING;

ANESTHESIA; ANIMALS; FEMALE; IMAGE PROCESSING, COMPUTER-ASSISTED; LIGANDS; MALE; OCTREOTIDE; PAPIO; QUALITY CONTROL; RADIOMETRY; RADIOPHARMACEUTICALS; RECEPTORS, SOMATOSTATIN; TOMOGRAPHY, EMISSION-COMPUTED; YTTRIUM RADIOISOTOPES;

EID: 0000525540     PISSN: 03406997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002590050398     Document Type: Article

References (33)

1. 90Y]-SMT487) eradicates experimental rat pancreatic CA 20948 tumors. Eur J Nucl Med 1998; 25: 668-674.
2. 3]octreotide, a promising somatostatin analogue for radionuclide therapy. Eur J Nucl Med 1997; 24: 368-371.
3. 3. Otte A, Jermann E, Behe M, Goetze M, Bucher HC, Roser HW, Heppeler A, Mueller-Brand J, Maecke HR. DOTATOC: a powerful new tool for receptor-mediated radionuclide therapy. Eur J Nucl Med 1997; 24: 792-795.
4. 4. Otte A, Mueller-Brand J, Dellas S, Nitzsche EU, Herrmann R, Maecke HR. Yttrium-90-labelled somatostatin analogue for cancer treatment. Lancet 1998; 7: 417-418.
5. 5. Stewart JSW, Hird V, Snook D, et al. Intraperitoneal yttrium-90-labelled monoclonal antibody in ovarian cancer. J Clin Oncol 1990; 8: 1941-1950.
6. 90Y-labelled monoclonal antibodies for ovarian cancer: pharmacokinetics and normal tissue dosimetry. Int J Cancer 1988; 3: 71s-76s.
7. 7. Dunscombe PB, Bhattacharyya AK, Dale RG. The assessment of the body distribution of yttrium-90 ferric hydroxide during radiation synovectomy. Br J Radiol 1976; 49: 372-373.
8. 90Y uptake in Baker's cysts: Its application in radiation synovectomy of the knee. Eur J Nucl Med 1988; 14: 498-503.
9. 90Y in patients with Baker's cyst and persistent synovitis of the knee. Ann Rheum Dis 1988; 47: 553-558.
10. 10. Mullan BP, Surveyor I. Imaging yttrium-90 synovectomy studies. Austral Radiol 1989; 33: 379-381.
11. 11. Kutzner J, Hahn K, Beyer GJ, Grimm W, Bockisch A, Rösler HP. Scintigraphic use of Y-87 during Y-90 therapy of bone metastases. Nucl Med 1992; 31: 53-56.
12. 90Yttrium antiferritin - a new therapeutic radiolabelled antibody. Int J Radiat Oncol Biol Phys 1986; 12: 277-281.
13. 90yttrium antiferritin: dose escalation and tumor dose. Antibody Immunoconj Radiopharm 1988; 1: 163-168.
14. 90Y-labelled antiferritin in hepatoma. Int J Radiat Oncol Biol Phys 1988; 14: 1033-1042.
15. 90Y activity needed to achieve certain tumor radiation doses in colorectal cancer patients. Cancer Res 1990; 50: 1029s-1030s.
16. 16. Vriesendorp HM, Herpst JM, Germack MA, Klein JL, Leichner PK, Loudenslager DM, Order SE. Phase I-II studies of yttrium-labelled antiferritin treatment for endstage Hodgkin's disease, including radiation therapy oncology group 87-01. J Clin Oncol 1991; 9: 918-928.
17. 17. Zimmer AM, Kuzel TM, Spies WG, et al. Comparative pharmacokinetics of In-111 and Y-90 B72.3 in patients following single dose intravenous administration. Antibody Immunoconj Radiopharm 1992; 5: 285-294.
18. 18. Carrasquillo JA, White JD, Paik CH, et al. Biodistribution of In-111 vs Y-90 labelled anti-tac monoclonal antibody. Proceedings of the 43rd Annual Meeting of the Society of Nuclear Medicine, Denver, Colorado, 3-5 June 1996, p. 234.
19. 19. Herzog H, Rösch F, Stöcklin G, Lueders C, Qaim SM, Feinendegen LE. Measurement of pharmacokinetics of yttrium-86 radiopharmaceuticals with PET and radiation dose calculation of analogous yttrium-90 radiotherapeutics. J Nucl Med 1993; 34: 2222-2226.
20. 20. Rösch F, Herzog H, Plag C, Neumaier B, Braun U, Müller-Gärtner H-W, Stöcklin G. Radiation doses of yttrium-90-citrate and yttrium-90-EDTMP. Eur J Nucl Med 1996; 23: 958-966.
21. 3He,2n)-processes. Radiochim Acta 1993; 61: 1-8.
22. 86Y for nuclear medical application. Appl Radiat Isot 1993; 44: 677-681.
23. 23. Albert R, Smith-Jones P, Stolz B, Simeon C, Knecht H, Bruns C, Pless J. Direct synthesis of [DOTA-DPhe(1)]-octreotide and [DOTA-DPhe(1),Tyr(3)]-octreotide (SMT487) - two conjugates for systemic delivery of radiotherapeutical nuclides to somatostatin receptor positive tumors in man. Bioorg Med Chem Lett 1998; 8: 1207-1210.
24. 24. Bernard BF, Krenning EP, Breeman WA, Rolleman EJ, Bakker WH, Visser TJ, Macke H, de Jong M. D-Lysine reduction of 111-indium octreotide and yttrium-90 octreotide renal uptake. J Nucl Med 1997; 38: 1929-1933.
25. 25. Rota Kops E, Herzog H, Schmid A, Holte S, Feinendegen LE. Performance characteristics of an eight-ring whole-body PET scanner. J Assist Comput Tomogr 1990; 61: 1-8.
26. 26. ICRP Publication 26. Recommendations of the International Commission on Radiological Protection. New York: Pergamon Press 1977.
27. 27. Cloutier RJ, Smith SA, Watson EE et al. Dose to the fetus from radionuclides in the bladder. Health Phys 1973; 25: 147-161.
28. 28. Stabin MG. MIRDOSE: personal computer software for internal dose assessment in nuclear medicine. J Nucl Med 1996, 37: 538-546.
29. 29. Mogensen CE, Sølling K. Studies on renal tubular protein reabsorption: partial and near complete inhibition by certain amino acids. Scand J Clin Lab Invest 1977; 37: 477-486.
30. 30. Castellino P, Levin R, Shohat J, DeFronzo RA. Effect of specific amino acid groups on renal hemodynamics in humans. Am J Physiol 1990; 258: F992-F997.
31. 31. Castellino P, DeFronzo RA. Effect of plasma amino acid and hormone concentration on renal plasma flow and glomerular filtration rate. Blood Purif 1988; 6: 240-249.
32. 32. Stabin MG, Kooij PP, Bakker WH, Inoue T, Endo K, Coveney J, de Jong R, Minegishi A. Radiation dosimetry for indium-111-pentetreotide. J Nucl Med 1997; 38: 1919-1922.
33. 33. Hammond PJ, Wade AF, Gwilliam ME, et al. Amino acid infusion blocks renal tubular uptake of an indium-labelled somatostatin analogue. Br J Cancer 1993; 67: 1437-1439.